GlaxoSmithKline's venture arm in hunt for experimental Alzheimer's drugs, imaging agent; Prosensa advances two more DMD programs;

Conversation on Twitter :

 @FierceBiotech: Hirano bodies may block Alzheimer's-related cell death. More | Follow @FierceBiotech

 @JohnCFierce: So AstraZeneca and Ironwood are getting close. AZ pays $25M in cash, up to $125M in miles for China rights to linaclotide; sharing revenue. | Follow @JohnCFierce

 @RyanMFierce: e-Therapeutics (computer-enabled network pharmacology) has shelved a MRSA candidate to focus on cancer program. More (reg. req.) | Follow @RyanMFierce

> The president of GlaxoSmithKline ($GSK) investment arm SR One is in the hunt for biotech partners who have an imaging agent to diagnose Alzheimer's as well as an experimental therapeutic for the memory-wasting ailment. "My goal is to find players around the table who have both an imaging approach with a therapeutic approach and have them collaborate really closely," Jens Eckstein told Bloomberg. "You cannot have one without the other." GSK is joining the R&D migration away from patients with advanced cases and into the field of early-stage work, attempting to see if targeting amyloid beta early on can delay or prevent the disease. Story

> The Dutch biotech Prosensa says it's pushing two more of its Duchenne muscular dystrophy therapies into clinical development. The biotech says the EC has granted PRO045 and PRO053 an orphan drug designation. These compounds are designed to skip exons 45 and 53 of the dystrophin gene and are expected to enter clinical development within the next 6 months. Release

> The Israeli biotech Pharma Two B has raised $8 million to back its R&D work on a Parkinson's drug. Story

Pharma News

@FiercePharma: EMA says it's investigating Roche for possible shortcomings in pharmacovigilance. More | Follow @FiercePharma

> Eisai snags FDA nod for blockbuster hopeful Fycompa. Story

> Roche to shed 100 jobs in diabetes Dx revamp. Item

> Judge orders FDA to let Watson sell generic Actos. Article

Medical Device News

 @FierceMedDev: Roche Dx is slashing jobs as it rethinks its diabetes business. More | Follow @FierceMedDev

 @MarkHFierce: Scientists can produce stem cells in great numbers from cadaver scalp tissue. More | Follow @MarkHFierce

 @DamianFierce: Japan's Sysmex is in talks to buy Dune Medical Devices for $200M, according to a report. More | Follow @DamianFierce

> Allegro celebrates encouraging early data for lung cancer test. Article

> Philips Healthcare soars in Q3. Item

Biotech Research News

> Australian scientists grow HIV antibodies in cow's milk. More

> A transplant anti-rejection treatment could be the next cancer drug. Article

> Pluristem's placental stem cells combat fibrosis in preclinical test. Story

> Scientists produced stem cells from cadaver scalp tissue. Item

Pharma Manufacturing News

> China's WuXi AppTec opens biologics plant. More

> Mexico's Neolpharma snags Pfizer Puerto Rico plant. News

> Mylan buying vertically integrated SMS oncology plant. Story

And Finally… Researchers from North Carolina State University say they have boosted the potency of a compound that reactivates antibiotics against methicillin-resistant Staphylococcus aureus (MRSA). Release

 

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.